Financials data is unavailable for this security.
View more
Year on year Cara Therapeutics Inc 's revenues fell -49.92% from 41.87m to 20.97m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 85.47m to a larger loss of 118.51m.
| Gross margin | 74.66% |
|---|---|
| Net profit margin | -1,010.20% |
| Operating margin | -1,000.06% |
| Return on assets | -107.38% |
|---|---|
| Return on equity | -184.32% |
| Return on investment | -132.61% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Cara Therapeutics Inc fell by 10.47m. However, Cash Flow from Investing totalled 43.46m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 92.08m for operations while cash generated from financing totalled 38.15m.
| Cash flow per share | -2.03 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.2115 |
|---|---|
| Tangible book value per share | 0.2115 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.59 |
|---|---|
| Quick ratio | 4.48 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
